Entheon Biomedical (XCNQ:ENBI) Cash-to-Debt : No Debt ⁽¹⁾ (As of Nov. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Entheon Biomedical's cash to debt ratio for the quarter that ended in Nov. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Entheon Biomedical could pay off its debt using the cash in hand for the quarter that ended in Nov. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Entheon Biomedical's Cash-to-Debt or its related term are showing as below:

XCNQ:ENBI' s Cash-to-Debt Range Over the Past 10 Years
Min: 14.96 Med: No Debt Max: No Debt
Current: No Debt

During the past 7 years, Entheon Biomedical's highest Cash to Debt Ratio was No Debt. The lowest was 14.96. And the median was No Debt.

XCNQ:ENBI's Cash-to-Debt is ranked better than
99.74% of 1537 companies
in the Biotechnology industry
Industry Median: 6.49 vs XCNQ:ENBI: No Debt

Entheon Biomedical Cash-to-Debt Historical Data

The historical data trend for Entheon Biomedical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Entheon Biomedical Cash-to-Debt Chart

Entheon Biomedical Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Nov21

Nov22

Nov23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Entheon Biomedical Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Entheon Biomedical's Cash-to-Debt

For the Biotechnology subindustry, Entheon Biomedical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entheon Biomedical's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's Cash-to-Debt falls into.

Entheon Biomedical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Entheon Biomedical's Cash to Debt Ratio for the fiscal year that ended in Nov. 2023 is calculated as:

Entheon Biomedical had no debt ⁽¹⁾.

Entheon Biomedical's Cash to Debt Ratio for the quarter that ended in Nov. 2023 is calculated as:

Entheon Biomedical had no debt ⁽¹⁾.

Entheon Biomedical (XCNQ:ENBI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Entheon Biomedical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Entheon Biomedical (XCNQ:ENBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ENTBF:USA 1XU1:Germany

Address

999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5

Website

https://www.entheonbiomedical.com

Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines

Entheon Biomedical (XCNQ:ENBI) Cash-to-Debt : No Debt (1) (As of Nov. 2023)